The history of the Flu Vaccine from 1940 to 2030

In 1918, about 50 million people, or one-fifth of the world’s population, became infected with the virus known as the “Spanish” flu, according to the Centers for Disease Control and Prevention (CDC).

“The 1918 Pandemic was the reason the military was so invested in getting a vaccine during World War II. They had seen what happened during World War I,” said Catherine Troisi, Ph.D., infectious disease epidemiologist and an associate professor at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.

Developing an influenza vaccine took more than a decade. Clinical trials began in the 1930s and researchers worked closely with U.S. military officials during World War II. In 1945, the first flu vaccine was approved for military use in the U.S. The following year, the vaccine was approved for civilians.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO enters 2024 with 90% of revenue guidance already contracted

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced an unaudited trading update for the year ended 31 December 2023. Highlights • Full year revenue of £56.0 million,

    hVIVO plc

    A day in the life of a Laboratory Team Leader at hVIVO

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Companies to follow in 2024: hVIVO

    Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

    hVIVO plc

    FluCamp 2023: Year in Review

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical

    hVIVO plc

    Irish-listed Hvivo signs €7.3m contract with biotechnology firm

    Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client. Irish-founded Hvivo runs drug trials known as challenge studies from its London clinics. The company will test the biotechnology’s client’s antiviral candidate

    hVIVO plc

    hVIVO appoints Nominated Adviser and Joint Broker

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as

    hVIVO plc

    Hvivo signs €7.3m contract to test cold virus treatment

    Hvivo, the pharmaceutical services company formerly known as Open Orphan, has signed a contract worth £6.3 million (€7.3 million) to test a potential treatment for the common cold. The contract, which is with an unnamed biotechnology

    hVIVO plc

    hVIVO plc £6.3m HRV Contract Signed with Biotechnology Client

    hVIVO plc (Euronext / LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using

    hVIVO plc

    hVIVO reels in £16.8M clinical trial deal for RSV drug

    London-based CRO hVIVO has landed a £16.8 million ($21 million) contract from an unnamed drugmaker to conduct a phase 2 trial of its respiratory syncytial virus (RSV) antiviral drug candidate. The company, which hVIVO has only described as a